|
|
From PCOS to PMOS: A More Accurate Name for a Complex Condition
|
|
By Laura Neville, ND | June 30, 2026
|
The condition formerly known as Polycystic Ovary Syndrome (PCOS) affects about 1 in 8 women worldwide, yet its name has never fully reflected what the condition actually is.
For many years, the term PCOS suggested that ovarian cysts were the defining feature of the condition. In reality, women with PCOS do not have an increased number of pathological ovarian cysts. This misleading name has often created confusion for patients and healthcare providers, contributed to delays in diagnosis, and reinforced stigma surrounding the condition.
To better reflect current scientific understanding, an international group of patients, clinicians, researchers, and healthcare organizations has adopted a new name: Polyendocrine Metabolic Ovarian Syndrome (PMOS).
|
|
|
|
|
|
|
A Global Effort
The transition from PCOS to PMOS followed one of the largest international consensus processes ever undertaken for a women's health condition. More than 14,000 survey responses, numerous workshops, and participation from patients, healthcare professionals, and organizations across the globe helped shape the new terminology.
A coordinated three-year implementation plan is now underway to update clinical guidelines, educational materials, research publications, healthcare systems, and disease classification codes.
|
|
|
|
|
|
|
Why the Name Change?
Research over the past several decades has shown that this condition is much more than an ovarian disorder. PMOS involves complex interactions between multiple hormone systems and metabolism, affecting many aspects of health throughout a woman's life.
The new name was chosen because it better describes the three major components of the condition:
-
Polyendocrine – multiple hormone systems are involved, including insulin, androgens, reproductive hormones, and neuroendocrine pathways.
-
Metabolic – insulin resistance and metabolic dysfunction are central features of the condition.
-
Ovarian – ovarian dysfunction remains a key aspect of diagnosis and symptom development.
|
|
|
|
|
|
|
The Importance of the Metabolic Component
One of the strongest reasons for including "metabolic" in the new name is the growing evidence that metabolic dysfunction is at the core of PMOS.
Most individuals with PMOS experience some degree of insulin resistance, which contributes to elevated androgen levels and worsens many symptoms of the condition. Obesity—especially increased abdominal fat—can further amplify hormonal and metabolic disturbances.
Women with PMOS have higher rates of:
-
Impaired glucose tolerance
-
Gestational diabetes
-
Type 2 diabetes
-
Dyslipidemia
-
Hypertension
-
Fatty liver disease
-
Cardiovascular disease
Research also shows increased risks of heart attack, stroke, and other cardiovascular complications compared with women who do not have PMOS.
|
|
|
|
|
|
|
Why This Matters
The previous name often led people to focus solely on the ovaries and fertility concerns, overlooking the broader hormonal and metabolic aspects of the condition. This contributed to:
-
Delayed diagnosis
-
Incomplete treatment approaches
-
Patient frustration and dissatisfaction
-
Persistent misconceptions about the condition
-
Challenges in research, healthcare policy, and disease classification
By adopting the name Polyendocrine Metabolic Ovarian Syndrome, healthcare professionals hope to improve awareness, diagnosis, treatment, research, and patient outcomes while reducing stigma and confusion.
|
|
|
|
|
|
|
PMOS Is a Whole-Body Condition
PMOS can affect many different systems in the body.
Metabolic features may include:
-
Insulin resistance
-
Weight gain and obesity
-
Prediabetes and type 2 diabetes
-
High blood pressure
-
Abnormal cholesterol levels
-
Fatty liver disease
-
Increased cardiovascular risk
-
Sleep apnea
Reproductive features may include:
-
Irregular menstrual cycles
-
Ovulatory dysfunction
-
Infertility
-
Pregnancy complications
-
Increased risk of endometrial cancer
Dermatologic features may include:
-
Acne
-
Excess facial or body hair (hirsutism)
-
Hair thinning or loss (alopecia)
Psychological features may include:
-
Anxiety
-
Depression
-
Eating disorders
-
Reduced quality of life
|
|
|
|
|
|
|
How Is PMOS Diagnosed?
The diagnostic criteria for Polyendocrine Metabolic Ovarian Syndrome (PMOS) remain the same as those previously used for PCOS. The name has changed, but the diagnostic framework has not changed.
Adult Diagnostic Criteria (Modified Rotterdam Criteria)
A diagnosis of PMOS is made when two of the following three criteria are present, after excluding other conditions that can cause similar symptoms:
1. Ovulatory Dysfunction
Evidence of infrequent or absent ovulation, including:
-
Irregular menstrual cycles
-
Oligomenorrhea (infrequent periods)
-
Amenorrhea (absence of periods)
-
Anovulation
2. Hyperandrogenism
Clinical and/or biochemical evidence of androgen excess.
Clinical signs may include:
-
Hirsutism (excess facial or body hair)
-
Acne
-
Androgenic alopecia (female-pattern hair loss)
Biochemical evidence may include elevated:
-
Free testosterone
-
Total testosterone
-
Free androgen index
-
Androstenedione
-
DHEA-S (less specific)
3. Ovarian Dysfunction
Either:
-
Polycystic ovarian morphology (PCOM) on ultrasound
OR
-
Elevated Anti-Müllerian Hormone (AMH) levels (now accepted in adults in the most recent international guidelines as an alternative to ultrasound in many situations)
|
|
|
|
|
|
|
Clinical Physical Assessments for PMOS
The evaluation of PMOS includes a comprehensive clinical assessment to identify the endocrine, metabolic, reproductive, dermatologic, and cardiovascular manifestations of the condition.
Anthropometric Measurements
-
Height
-
Weight
-
Body Mass Index (BMI)
-
Waist circumference
-
Hip circumference
-
Waist-to-hip ratio
-
Body composition assessment (body fat percentage, visceral adiposity, lean muscle mass)
Vital Signs
-
Blood pressure
-
Resting heart rate
Menstrual and Reproductive Assessment
-
Age at menarche
-
Menstrual cycle length and regularity
-
Frequency of ovulation
-
Fertility history
-
Pregnancy history and complications
-
Assessment of menopausal status when applicable
Hyperandrogenism Assessment
Hirsutism
-
Modified Ferriman-Gallwey (mFG) Score (Remains the standard clinical tool for evaluating hirsutism)
-
Assesses terminal hair growth in androgen-sensitive areas
Acne Assessment
-
Distribution and severity of acne
-
Presence of persistent adult-onset acne
Alopecia Assessment
-
Female-pattern hair loss
-
Thinning at the crown or widening of the central hair part
Dermatologic Assessment
-
Acanthosis nigricans (marker of insulin resistance)
-
Skin tags (acrochordons)
-
Seborrhea
-
Hyperpigmentation
Metabolic Assessment
-
Central adiposity (abdominal fat distribution)
-
Evidence of insulin resistance
-
Weight history and weight gain patterns
-
Assessment of physical activity levels
-
Dietary assessment
Cardiometabolic Assessment
-
Cardiovascular risk factors
-
Family history of diabetes
-
Family history of cardiovascular disease
-
Sleep quality assessment
-
Screening for obstructive sleep apnea symptoms
-
Snoring
-
Daytime fatigue
-
Witnessed apneas
Psychological Assessment
-
Depression screening
-
Anxiety screening
-
Assessment of quality of life
-
Body image concerns
-
Eating disorder screening
-
Stress assessment
Functional and Lifestyle Assessment
-
Exercise habits
-
Sleep duration and quality
-
Stress levels
-
Dietary patterns
-
Tobacco use
-
Alcohol consumption
-
Medication and supplement review
Differential Diagnosis Assessment
Physical examination should also evaluate for signs suggesting alternative diagnoses, including:
Cushing Syndrome
-
Purple striae
-
Proximal muscle weakness
-
Easy bruising
-
Moon facies
Thyroid Disease
-
Goiter
-
Dry skin
-
Hair changes
-
Bradycardia or tachycardia
Androgen-Secreting Tumors
-
Rapid onset hirsutism
-
Virilization
-
Clitoromegaly
-
Deepening voice
-
Increased muscle mass
|
|
|
|
|
|
|
Clinical Testing Considerations
Blood Markers Commonly Used in the Conventional Assessment of PMOS
Androgen Assessment
-
Total Testosterone
-
Free Testosterone
-
Sex Hormone-Binding Globulin (SHBG)
-
Dehydroepiandrosterone Sulfate (DHEA-S)
-
Androstenedione
-
Dihydrotestosterone (DHT) (optional)
Ovarian Function
-
Anti-Müllerian Hormone (AMH)
-
Luteinizing Hormone (LH)
-
Follicle-Stimulating Hormone (FSH)
-
LH Ratio
-
Estradiol (E2)
-
Progesterone (timed to cycle phase)
Metabolic Assessment
-
Fasting Glucose
-
Fasting Insulin
-
Hemoglobin A1c (HbA1c)
-
Oral Glucose Tolerance Test (OGTT) with Insulin (when indicated)
-
HOMA-IR (calculated from fasting glucose and insulin)
Cardiometabolic Risk
-
Total Cholesterol
-
LDL Cholesterol
-
HDL Cholesterol
-
Triglycerides
-
Apolipoprotein B (ApoB)
-
Lipoprotein(a) [Lp(a)]
-
High-Sensitivity C-Reactive Protein (hs-CRP)
Adrenal Function
-
DHEA or DHEA-S (serum or salivary)
-
Cortisol (serum or salivary)
-
17-Hydroxyprogesterone (to rule out non-classic congenital adrenal hyperplasia)
Thyroid Assessment
-
Thyroid-Stimulating Hormone (TSH)
-
Free T4
-
Free T3
-
Thyroid Peroxidase Antibodies (TPOAb)
-
Thyroglobulin Antibodies (TgAb)
Prolactin and Pituitary Evaluation
Liver and Metabolic Health
-
ALT
-
AST
-
Gamma-Glutamyl Transferase (GGT)
-
Comprehensive Metabolic Panel (CMP)
Additional Markers Often Considered
-
Vitamin D (25-OH Vitamin D)
-
Ferritin
-
Vitamin B12
-
Homocysteine
-
Magnesium
-
Uric Acid
Emerging or Advanced Markers
-
Fasting Insulin-like Growth Factor-1 (IGF-1)
-
Adiponectin
-
Leptin
-
Leptin Ratio
-
Oxidized LDL
-
Advanced Lipoprotein Testing
-
Inflammatory Cytokines
Differential Diagnosis Testing
Laboratory testing may also be used to rule out conditions that can mimic PMOS, including:
-
Thyroid disorders
-
Hyperprolactinemia
-
Non-classic congenital adrenal hyperplasia
-
Cushing syndrome
-
Androgen-secreting ovarian or adrenal tumors
-
Primary ovarian insufficiency
Core Laboratory Panel
If the goal is to identify the most clinically useful markers, a core PMOS panel would typically include:
-
Total Testosterone
-
Free Testosterone
-
SHBG
-
DHEA-S
-
AMH
-
LH
-
FSH
-
Estradiol
-
Progesterone (timed to cycle phase)
-
Fasting Glucose
-
Fasting Insulin
-
HbA1c
-
Lipid Panel
-
hs-CRP
-
TSH
-
Free T4
-
Prolactin
-
17-Hydroxyprogesterone
-
Vitamin D
This combination evaluates the key endocrine, ovarian, metabolic, inflammatory, and cardiometabolic components that characterize PMOS.
|
|
|
|
|
|
|
Doctor’s Data Testing
Beyond standard serum labs, Doctors Data testing can also help provide valuable information for clinicians and patients when PMOS is suspected.
Both salivary (i.e. the Comprehensive Hormone Profile) and urinary hormone testing (HuMap) can be key tools in the assessment of PMOS. In particular, salivary testing (representing tissue hormone levels) may detect elevations in testosterone and/or DHEA before these changes become apparent on standard serum testing. In contrast, urinary testing is often more reflective of serum values, but can provide deeper insight into the androgenic changes, such as shuttling testosterone into DHT, that are frequently associated with PMOS. Early detection can provide clinicians with an opportunity to implement targeted interventions sooner, potentially preventing hormonal and metabolic dysfunction from becoming more established. When used alongside a comprehensive clinical evaluation and conventional laboratory testing, salivary and urinary hormone assessments may offer additional insights into underlying hormonal and metabolic imbalances.
|
|
|
|
|
|
|
Conclusion
The transition from PCOS to PMOS represents far more than a simple name change—it reflects a significant evolution in our understanding of this common and complex condition. By recognizing the central roles of endocrine dysfunction, metabolic health, and ovarian function, the new terminology more accurately captures the multisystem nature of the disorder and helps move the conversation beyond a narrow focus on ovarian morphology and fertility.
Early identification through a comprehensive assessment that includes clinical evaluation, metabolic screening, and hormone testing can provide valuable opportunities for timely intervention and improved long-term outcomes. As awareness of PMOS continues to grow, a more holistic and individualized approach to diagnosis and treatment has the potential to enhance patient care, reduce stigma, and improve the health and quality of life of the millions of women affected worldwide.
|
|
|
|
|
|
|
References
-
Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
-
Berni TR, Morgan CL, Rees DA. Women with polycystic ovary syndrome have an increased risk of major cardiovascular events: a population study. J Clin Endocrinol Metab. 2021;106(9).
-
Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32(5):1075-1091.
-
Dewailly D, Lujan ME, Carmina E, et al. Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and PCOS Society. Hum Reprod Update. 2014;20(3):334-352.
-
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270-284.
-
Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis. Hum Reprod Update. 2013;19(6):721-732.
-
International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. International PCOS Network; 2023.
-
Joham AE, Norman RJ, Stener-Victorin E, et al. Summary of the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome: an Australian perspective. Med J Aust. 2024;221(7):336-344.
-
Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2018;24(4):455-467.
-
Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019;20(2):339-352.
-
Neven ACH, Forslund M, Ranasinha S, et al. Prevalence of polycystic ovary syndrome: a global and regional systematic review and meta-analysis. Hum Reprod Update. 2026;32(3):277-312. doi:10.1093/humupd/dmaf030.
-
Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocr Rev. 2016;37(5):467-520.
-
Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25.
-
Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi:10.1016/S0140-6736(26)00717-8.
-
Teede HJ, Misso ML, Costello MF, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602-1618.
-
Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-Based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Eur J Endocrinol. 2023;189(2). doi:10.1093/ejendo/lvad096.
|
|
|
|
|
|
|
|
ADHD in Perimenopause: The Estrogen-Dopamine Connection and Clinical Implications
Presented by Ruth Hobson, ND | July 1, 2026 at 12 PM Pacific
|
|
|
|
|
|
|
ADHD is significantly underdiagnosed in women, many of whom are not identified until adulthood, often around age 36 to 38, largely due to gender biased symptom recognition and limited awareness of how hormonal changes across the female lifespan impact the condition. Estrogen plays a central role in regulating dopamine and serotonin, making women particularly vulnerable to symptom fluctuations during puberty, menstruation, postpartum, and perimenopause. Declining estrogen can worsen inattention, impulsivity, and emotional instability through reduced dopamine availability.
Growing research also points to the gut brain axis as a factor in ADHD, with gut microbiota influencing neurotransmitter production and brain function. Dysbiosis has been linked to greater symptom severity, driving interest in integrative approaches such as probiotics, dietary interventions, and microbiome focused care.
With diagnoses among adult women rising sharply, primary care providers are well positioned to close the recognition gap. This presentation equips clinicians with practical, evidence based tools integrating hormonal, neurochemical, and gut health perspectives to support more accurate diagnoses and individualized care.
|
Learning Objectives:
- Identify key factors in making an ADHD diagnosis and factors that may contribute to a delayed presentation of ADHD in female patients
- Explain the relationship between estrogen and neurotransmitter function, particularly the modulation of dopamine and serotonin, and how fluctuations in these systems influence ADHD symptoms.
- Describe the role of the gut-brain axis and microbiome in ADHD pathophysiology, including how dysbiosis can contribute to neuroinflammation and neurotransmitter imbalance.
- Assess ADHD symptoms in women within the context perimenopause
- Apply integrative approaches in primary care to support female patients with ADHD, including nutritional interventions, adaptogens, probiotics, and lifestyle modifications.
|
|
|
|
|
|
|
|
The Estrobolome: How Gut Dysbiosis and Liver Detoxification Shape Estrogen Balance
Presented by Dan Kalish, DC | July 7, 2026 at 12 PM Pacific
|
|
|
|
|
|
|
Estrogen balance is shaped by more than hormone production. It also depends on gut microbiome health, liver detoxification, and the body's ability to properly eliminate or recycle estrogen.
This class explains how the estrobolome influences estrogen metabolism, how Phase II liver detoxification prepares estrogen for excretion, and how gut dysbiosis and beta-glucuronidase activity can lead to excess estrogen recycling and hormone-related symptoms.
|
Learning Objectives:
- Understand the role of the estrobolome in estrogen regulation.
- Map the connection between liver detoxification, gut excretion, and estrogen recycling.
- Learn how beta-glucuronidase can reactivate estrogen for reabsorption.
- Recognize how gut dysbiosis may contribute to estrogen dominance.
- Identify key stool and hormone biomarkers related to estrogen clearance
|
|
|
|
|
|
|
Disclaimer: All information given about health conditions, treatment, products, and dosages are for educational purposes only and do not constitute medical advice.
|
|
|
|
|
|
|
800.323.2784 (US and Canada)
+1.630.377.8139 (Global)
|
|
|
|
|
|
